Clinical trials · Denver, CO
Interstitial Lung Disease clinical trials in Denver
We’re tracking 19 recruiting interstitial lung disease studies with a site in or near Denver — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Denver
- NCT06129240Recruiting
Study of a new inhaled treprostinil powder for PH-ILD
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
Denver, ColoradoAges 18–80 - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Denver, ColoradoAges 18 years+ - NCT06911632Recruiting
AI-assisted check for pulmonary hypertension in interstitial lung disease
This study uses an AI tool to help doctors decide if you should be tested for pulmonary hypertension (high blood pressure in the lungs), which can be a complication of interstitial lung disease. If the tool suggests you might have it, you may get an echocardiogram (an ultrasound of the heart) and a right heart catheterization (a test to measure pressure in the heart) to find out for sure.
Denver, ColoradoAges 18 years+ - NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Denver, ColoradoAges 18 years+ - NCT06806592RecruitingPhase 3
Testing nerandomilast for lung scarring from rheumatic disease
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
Denver, ColoradoAges 18 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Denver, ColoradoAges 40 years+ - NCT07704567Recruiting
Using MoblO2 to maintain oxygen levels during activity
This study tests a device called MoblO2 to help people with COPD or interstitial lung disease keep their oxygen levels up during activity. If you normally use oxygen when you walk or exert yourself, this might help you stay active more safely.
Denver, ColoradoAges 25–95 - NCT07714252Enrolling by invitation
Virtual palliative care team for veterans with heart or lung disease
This study tests a virtual team of nurses and social workers who provide palliative care to veterans with heart failure, COPD, or interstitial lung disease. The goal is to improve quality of life by offering extra support at home.
Aurora, ColoradoAges 18 years+ - NCT05001009Enrolling by invitation
Goals of care conversation support for certain serious illnesses
This study helps primary care clinicians and their patients have structured “goals of care” conversations (about what matters most and care preferences). It may help you get clearer, earlier planning—especially if you have a serious illness and higher risk of hospitalization or death.
Aurora, ColoradoAges 18 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Aurora, ColoradoAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Aurora, ColoradoAges 18 years+ - NCT06855329Recruiting
Studying progressive lung scarring (non-IPF)
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
Aurora, ColoradoAges 18–80 - NCT06397677Recruiting
Study of Progressive RA Interstitial Lung Disease
This study is looking at people with rheumatoid arthritis (RA) who also have interstitial lung disease (ILD), a condition that causes scarring in the lungs. It aims to understand how the disease changes over time by using imaging and blood tests, without providing any new treatments right now.
Aurora, ColoradoAges 18–90 - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Aurora, ColoradoAges 21 years+ - NCT07366034RecruitingPhase 3
Testing nerandomilast for children with lung scarring
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Aurora, ColoradoAges 2–17 - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Aurora, ColoradoAges 40 years+ - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Aurora, ColoradoAges 18 years+ - NCT07175038RecruitingPhase 2
Study of a new pill for pulmonary hypertension
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Aurora, ColoradoAges 18–80 - NCT03297775Recruiting
Studying rheumatoid arthritis treatment risks for lung scarring
This trial is for people with rheumatoid arthritis (RA) who are at risk for developing interstitial lung disease, which is scarring in the lungs. It aims to better understand why this happens and how to help prevent or manage it.
Aurora, ColoradoAges 45–90
Hear when a new Interstitial Lung Disease trial opens near Denver, CO
We’ll email you when one opens near Denver, CO — at most once a week, no account needed, unsubscribe anytime.
Interstitial Lung Disease trials in other cities
Where these studies are running near Denver
Institutions with a site for the recruiting interstitial lung disease studies listed above.
- National Jewish Health · 6 studies
- University of Colorado Anschutz Medical Campus · 6 studies
- Rocky Mountain Regional VA Medical Center · 2 studies
- UCHealth University of Colorado Hospital · 2 studies
- Children's Hospital Colorado
- GSK Investigational Site
- Rocky Mountain Cancer Centers
- Sarah Cannon Research Institute
What taking part in a interstitial lung disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting interstitial lung disease studies in Colorado.
Common questions
- Are there interstitial lung disease clinical trials near Denver?
- Yes. We're currently tracking 19 recruiting interstitial lung disease studies with a site near Denver, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a interstitial lung disease study near Denver?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Denver to take part?
- Not necessarily. These studies have a site near Denver, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a interstitial lung disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New interstitial lung disease studies open near Denver regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.